SYNGENE
LIVE

Serial Number

88981754

Owner

SYNGENE INTERNATIONAL LIMITED

Attorney

Julianne Abelman

First Use Date

Aug 31, 2004

Filing Date

Aug 16, 2018

Add to watchlist:

No watchlists yet
View on USPTO

SYNGENE Trademark

Serial Number: 88981754 • Registration: 6405032

SYNGENE is a trademark filed by SYNGENE INTERNATIONAL LIMITED on August 16, 2018. The trademark is classified under Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

SYNGENE INTERNATIONAL LIMITED (13 trademarks)

Biocon Special Economic Zone,Biocon Park
Link Rd, Bangalore Karnataka , IN

Entity Type: 03

Trademark Details

Filing Date

August 16, 2018

Registration Date

June 29, 2021

First Use Anywhere

August 31, 2004

First Use in Commerce

August 31, 2004

Published for Opposition

January 14, 2020

Goods & Services

Scientific research and custom synthesis; scientific and clinical research in the field of medicine, pharmaceutical, nutraceuticals; scientific research and development; custom design and development of chemical reagents and biochemical assays; laboratory testing; laboratory testing services for research and development purposes; testing of pharmaceuticals; chemical engineering; drug discovery services; pharmaceutical drug development services; pharmaceutical products development; development of pharmaceutical preparations and medicines; scientific study and research in the field of reproduction, husbandry, and general health of animal; biotechnology research for determining the neuronal survival of molecules in animal models; research and development services in the field of antibodies, antibody technology; custom design and development of chemical reagents and biochemical assays; design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; toxicology services; toxicity analysis; toxicity testing for research purposes; conducting clinical trials; conducting clinical trials for scientific research for others; conducting clinical trials for pharmaceutical products; providing medical and scientific research information in the field of clinical trials; conducting early evaluations in the field of new pharmaceuticals; DNA analysis services for scientific research purposes; laboratory research in the field of gene expression; blood analysis services for scientific research purposes; analysis of human tissues for medical research; scientific services relating to the isolation and cultivation of human tissues and cells for research purposes; preparation of reports relating to scientific and technical research; analysis in the field of molecular biology; contract research services relating to molecular sciences; biological cloning services; structural and functional analysis of genomes; scientific and medical laboratory services; services of a chemical and/or biological laboratory; laboratory research services relating to pharmaceuticals; research and development and consultation related thereto in the field of antibodies, antibody technology, chemistry, bioinformatics, biomedical devices, biologics, biotechnology, biotherapeutics, biology, biochemical preparations, cell lines, cheminformatics, genetics and genetic engineering, gene expression systems, in vitro research, inhalation pharmaceuticals, molecular sciences, micro-organisms, nutrition, ophthalmic preparations, pharmacogenetics, pharmacokinetics, pharmacology, pharmaceuticals, polymers, peptide synthesis, protein, and solid state characterization; toxicokinetic analysis and toxicology services; scientific and technological services, namely, scientific research, development, analysis, testing, engineering, extraction, synthesis, purification and production in the field of antibodies, active pharmaceutical ingredients (API), biomolecules, cell bank characterization, chirality, chromosome aberration, clinical chemistry, cloning vector, cyclotides, DNA, flow cytometry, gas chromatography mass spectrometry, genes, immuno-pharmaceuticals, in vitro irritation, large molecule, liquid chromatography mass spectrometry, microbials, monomers, nanoparticles, natural products, peptides, proteins, RNA, supercritical fluid chromatography, small molecules and vaccines; none of the aforesaid services relating to gel imaging and gel analysis applications, and none of the aforesaid services in the field of agriculture, horticulture and forestry

Business services, namely, formulation of best practices for drug discovery, formulation development, clinical supplies, large molecule development, antibody drug conjugates and clinical development services; consulting services in the field of medical practice management for others; business consulting and management in the field of clinical trials, namely, providing information management services; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies; business management consulting services in the field of pharmaceuticals drug development; none of the aforesaid services relating to gel imaging and gel analysis applications

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 29, 2026 REM1
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jun 2, 2023 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 2, 2023 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jun 2, 2023 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 2, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 2, 2023 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jun 2, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 2, 2023 COAR
REGISTERED-PRINCIPAL REGISTER
Jun 29, 2021 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
May 28, 2021 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 27, 2021 CNPR
STATEMENT OF USE PROCESSING COMPLETE
May 26, 2021 SUPC
DIVISIONAL PROCESSING COMPLETE
May 26, 2021 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 26, 2021 AITU
USE AMENDMENT FILED
May 6, 2021 IUAF
DIVISIONAL REQUEST RECEIVED
May 6, 2021 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
May 6, 2021 ERTD
TEAS STATEMENT OF USE RECEIVED
May 6, 2021 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2021 EXRA
SOU EXTENSION 1 GRANTED
Mar 1, 2021 EX1G
SOU EXTENSION 1 FILED
Mar 1, 2021 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 1, 2021 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 1, 2020 NOAM
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Jul 23, 2020 ETOP
POST PUBLICATION AMENDMENT - ENTERED
Jun 26, 2020 CHPB
ASSIGNED TO PETITION STAFF
Jun 24, 2020 APET
TEAS POST PUBLICATION AMENDMENT RECEIVED
Jun 2, 2020 EPPA
EXTENSION OF TIME TO OPPOSE RECEIVED
Feb 11, 2020 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 14, 2020 NPUB
PUBLISHED FOR OPPOSITION
Jan 14, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 25, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 12, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 11, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 11, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 11, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 11, 2019 GNRN
NON-FINAL ACTION E-MAILED
Jun 11, 2019 GNRT
NON-FINAL ACTION WRITTEN
Jun 11, 2019 CNRT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 4, 2019 TCCA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 4, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 4, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 4, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 6, 2018 GNRN
NON-FINAL ACTION E-MAILED
Dec 6, 2018 GNRT
NON-FINAL ACTION WRITTEN
Dec 6, 2018 CNRT
ASSIGNED TO EXAMINER
Dec 3, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 25, 2018 NWOS
NEW APPLICATION ENTERED
Aug 20, 2018 NWAP